Priyanka’s practice encompasses advising entities across the health care sector on complex transactions, compliance and regulatory matters, and state and federal government investigations. Her clients include life sciences companies, health care providers, payors, health insurers, laboratories, clinical-stage companies, diagnostic companies, pharmaceutical manufacturers, pharmacy benefit managers, and hospice and home health providers.
Priyanka’s corporate matters include mergers, acquisitions, divestitures, capital markets transactions, corporate governance matters, and financing matters. She has experience reviewing, drafting, and negotiating transaction documents, collaborating with specialist groups, and conducting due diligence reviews. She also regularly drafts agreements for pharmacy benefit managers, licenses, partnerships, joint ventures, and manufacturing arrangements as well as for strategic collaborations involving clinical-stage companies and pharmaceutical companies.
In the compliance side of her practice, Priyanka counsels clients on matters concerning the Federal Food, Drug, and Cosmetic Act (FDCA), False Claims Act (FCA), Anti-Kickback Statute (AKS), Stark Law, NY Health Laws, Medicare and Medicaid program requirements, Physician Payments Sunshine Act (Sunshine Act), Clinical Laboratory Improvement Amendments of 1988 (CLIA), and the Drug Supply Chain Security Act (DSCSA). Additionally, she represents health care and life sciences companies in state and federal government investigations.
Before joining Mintz, Priyanka was an associate in the Healthcare and the Food, Drug, and Medical Device practice areas of a global law firm. She also practiced as a corporate associate at her prior firm, gaining experience with transactions and drafting and negotiating a wide range of agreements.
In law school, Priyanka served as chief articles editor for UCLA Law’s Asian & Pacific American Law Journal and president of the Health Law Society. Priyanka earned her BA from the University of California, Berkeley.
viewpoints
Massachusetts Aligns with National Trends and Enacts Sweeping Legislation to Regulate Pharmaceutical Benefit Managers
January 24, 2025 | Blog | By Theresa Carnegie, Bridgette Keller, David Gilboa, Priyanka Amirneni
On the heels of a nationwide push to regulate pharmacy benefit managers (PBMs), Massachusetts enacted a landmark piece of legislation to increase transparency and oversight within the pharmaceutical supply chain, specifically targeting PBMs. Signed into law by Governor Healey on January 9, 2025, the comprehensive bill, titled “An Act Relative to Pharmaceutical Access, Costs and Transparency” (the Act), introduces a multifaceted approach that aims to reduce prescription drug costs, enhance data transparency, and impose stronger oversight of PBMs and pharmaceutical manufacturers.
